For more info: http://crme.realpennies.com
Cardiome Pharma Corp.
(Nasdaq: CRME) Current Price (8.48) VANCOUVER, March 17- Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced positive interim clinical results from its 90-day Phase 2b study of vernakalant (oral). The interim analysis demonstrated statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo. The safety data from the interim analysis also suggests that vernakalant (oral) was well-tolerated in the atrial fibrillation population studied during the dosing period under analysis. Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.
For more info: http://levp.realpennies.com
Lev Pharmaceuticals, Inc.
(OTCBB:LEVP) Current Price (.80) PHILADELPHIA & NEW YORK--Mar 18, 2008--Lev Pharmaceuticals, Inc. (OTCBB:LEVP.OB - News) today announced the presentation of results from a Phase III study examining the efficacy and safety of prophylactic use of its C1 inhibitor (C1INH) replacement therapy, Cinryze, in patients with hereditary angioedema (HAE). The findings, presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI), demonstrated that prophylactic use of Cinryze significantly decreases the number of attacks in HAE patients. Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's C1 inhibitor, proposed to be marketed as Cinryze(TM), has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. Lev has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs. Lev is also evaluating the development of C1 inhibitor for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.
For more info: http://bbox.realpennies.com
Black Box Corp.
(Nasdaq: BBOX) Current Price (28.60) PITTSBURGH--Mar 17, 2008--Black Box Corporation (NASDAQ:BBOX - News) today announced that it has acquired AT&T Inc.'s (NYSE:ATT - News) NEC TDM voice CPE business line in AT&T's southeast region. Black Box is the world's largest technical services company dedicated to designing, building and maintaining today's complicated data and voice infrastructure systems. Black Box services 175,000 clients in 141 countries with 187 offices throughout the world.
For more info: http://uspr.realpennies.com
US Precious Metals Inc.
(OTC BB: USPR Current Price (1.15) CELEBRATION, Fla.--Mar 18, 2008--U.S. Precious Metals, Inc. (OTCBB: USPR - News) USPR Board members Sheldon Baer and Jerry Payne were accompanied by USPR investors, CEO Michael Floersch of Applied Minerals, Inc., President Dave Burney of USPR and Jose Garcia President of U.S. Precious Metals de Mexico along with other USPR staff members to the La Sabila Project site in southern Michoacan, Mexico on March 11th 2008. Director Baer said that the project tour focused on the progress of the drilling, evaluating the performance of the Niton XRF analyzer and the sampling of high grade zones of gold, silver and copper that were previously identified by USPR staff. The XRF analyzer proved very successful in identifying additional zones of gold, silver and copper mineralization. US Precious Metals, Inc. is a gold exploration company operating in Mexico through its wholly owned Mexican subsidiary, U.S. Precious Metals de Mexico. US Precious Metal's common stock is quoted on the OTC Bulletin Board under the symbol "USPR."
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment